A
Aphea.Bio
Food · Ghent, Belgium · Founded 2016
Develops microbial-based biostimulant and biocontrol products using a high-throughput platform to protect crops while reducing chemical inputs MoreLess
Aphea.Bio is a biotechnology startup that operates in the agricultural sector. The company focuses on the discovery and development of novel and unique strains of biologicals, with a proprietary collection of over 15,000 strains. These biologicals are used to create biocontrol and biostimulant products that help farmers maintain the health of their crops.
The company's business model is based on the use of advanced technologies such as microbiome mapping and high-throughput analytical methods to identify beneficial plant-microbe interactions. These technologies allow Aphea.Bio to screen thousands of potential product candidates quickly and efficiently.
Once potential candidates are identified, the company uses in-house data mining capabilities and expertise to evaluate these leads. This process involves high-throughput, automated plant phenotyping and AI-based disease scoring algorithms. The goal is to identify the candidates that will make a significant difference for the plants and, ultimately, the farmers.
The company also has an experienced team of field trial managers and scientific experts who implement extensive field trial programs. These programs, combined with the company's in-house data management and statistics system, allow Aphea.Bio to perform in-depth analysis of their data and steer their development process effectively.
In terms of revenue, Aphea.Bio likely makes money by selling their biocontrol and biostimulant products to farmers and agricultural businesses. The company's unique approach and proprietary strains give it a competitive edge in the market, potentially allowing it to charge premium prices for its products.
Keywords: Biotechnology, Agriculture, Biocontrol, Biostimulant, Microbiome Mapping, High-Throughput Analytical Methods, Data Mining, Plant Phenotyping, AI-Based Disease Scoring, Field Trial Programs.
Company overview
Aphea.Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Ghent, Belgium
- Employees
- 67
- Open positions
- None listed
- Dealroom signal
- 66.0
Valuation & funding
Aphea.Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Nov 2024 | $2.1M | — | VLAIO- Team Bedrijfstrajecten Crossroads France-Wallonie-Vlaanderen | ↗ |
| SERIES COther financing | Jul 2023 | $77M | $308M | Gemma Frisius Fund - GFF · Korys · SFPIM · V-Bio Ventures | ↗ |
| SERIES BOther financing | Dec 2021 | $20M | $79M | European Circular Bioeconomy Fund | ↗ |
| SERIES BOther financing | Apr 2021 | $4.4M | $77M | Qbic Fund · Gemma Frisius Fund - GFF · Agri Investment Fund · Flanders Institute for Biotechnology | — |
| SERIES BOther financing | Dec 2020 | $15M | $62M | Gemma Frisius Fund - GFF · Vives Partners · Astanor Ventures · PMV | — |
| GRANTOther financing | Jul 2017 | Undisclosed | — | ||
| SERIES AOther financing | Jun 2017 | Qbic Fund · Flanders Institute for Biotechnology · Vives Partners · Gemma Frisius Fund - GFF | — | ||
| SEEDOther financing | Jun 2016 | Flanders Institute for Biotechnology · V-Bio Ventures | — | ||
| SPINOUTOther financing | May 2016 | Ghent University · KU Leuven · Flanders Institute for Biotechnology | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin |
|---|---|---|
| 2026 | −$8.5M | — |
| 2025 | −$8.5M | — |
| 2024 | −$8.5M | — |
| 2023 | −$8.5M | — |
| 2022 | −$8.5M | — |
| 2021 | −$6.2M | — |
| 2020 | −$4.1M | — |
Growth signals
Aphea.Bio website traffic
Latest recorded traffic for Aphea.Bio is 5K monthly website visits, up 117.4% over the last three months. Aphea.Bio's team declined 8.2% over the past year.
Comparisons
Aphea.Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Aphea.Bio's talent
Source: Dealroom Talent Intelligence.
Investors
19 investors on Aphea.Bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Aphea.Bio has talent and traffic
team presence
In the news
Latest news about Aphea.Bio
Recent press, funding announcements, and product moves mentioning Aphea.Bio — open to read from the original sources.
Market sentiment
What the market is saying about Aphea.Bio
An AI-synthesized read of the highest-engagement posts about Aphea.Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aphea.Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.